Mauna Kea Tech : ologies announces CE mark for its novel near-infrared platform for endomicroscopic navigation during minimally invasive surgery

 New regulatory approval covers broad use of novel Cellvizio 800 platform

"This new regulatory step underlines our growing efforts and presence in the surgical arena through an expanded and dedicated product line," Sacha Loiseau, CEO and founder of Mauna Kea Technologies said. "With this novel endomicroscopy platform now operating in the same setting and the same wavelength as widely used macroscopic imaging surgical platforms, we are well positioned to take fluorescence-guided surgery to the next level of precision and reliability."
Image-guided surgery with intra-operative macroscopic fluorescence systems provides surgeons with immediate actionable information used to optimize surgical treatments. The Cellvizio 800 platform is complementary to most existing platforms such as the Pinpoint® or Firefly® systems.
This clearance also covers use of Cellvizio 800 in gastroenterology, pulmonary and urinary indications. Cellvizio 800 (formerly Cellvizio 785) had already obtained clearance from FDA in the US last year for GI endoscopy applications only.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on protecting patient lives by enabling physicians and surgeons

to make better decisions thanks to direct visualization at the cellular level. The company's flagship product, Cellvizio® has received clearance for a broad range of applications in more than 40 countries including the United-States, Europe, Japan, China, Canada, Brazil and Mexico. For further information on Mauna Kea Technologies, visit www.maunakeatech.com

Pinpoint and Firefly are registered trademarks of Novadaq Technologies Inc.

Eric Cohen

Vice President Finance

Tél. : +33 (0)1 70 08 09 70

investor-vpf@maunakeatech.com

NewCap - Investor Relations

Florent Alba / Pierre Laurent Tél. : +33 (0)1 44 71 94 94 maunakea@newcap.fr

1

distributed by